Ulixertinib (BVD-523, VRT752271) is a potent reversible ERK1/ERK2 inhibitor that inhibits the IC50 of ERK2 <0.3 nM. Phase 1.

 

Brand: BCM

 

Target: ERK

 

Signaling Pathways: MARK

 

Boiling Point: 682.8±55.0 °C(Predicted)

 

pKa: 13.34±0.50(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

GHS: GHS07

 

Isomeric SMILES: CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl  

 

InChIKey: KSERXGMCDHOLSS-LJQANCHMSA-N  

 

InChI: InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1

 

Attribute
[Chem Name]	N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide
[Synonym]	Ulixertinib; BVD-523; VRT752271
[CAS No.]	869886-67-9
[MDL No.]	MFCD22628898
[Formula]	C21H22Cl2N4O2
[Molecular]	433.33
[Form]	Powder
[Storage]	Inert atmosphere, 2-8°C

Goods Tag